ClinicalTrials.gg
Not yet recruitingNCT07628959LUNAUpdated Oct 2, 2026

Innovative Sleep Quality Analysis Software Compared With Polysomnography

An interventional study of C. Santé software compared to polysomnography in Sleep Disorder (Disorder), sponsored by Centre Hospitalier Universitaire de Saint Etienne. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 2, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Sleep Wake Disorders with a site in France — 22 open to participants now, 27 under way, 4 of them phase 3. Sleep Wake Disorders · France.

Planned enrollment
34th of 42
33 · median 87
Started
2026
with 8 others
No phase
29 of 65
11 open now
Primary completion
2026-12
later than 11 of 26 live
Registered
64th of 65
by date
Lead sponsor
2 of 65
Centre Hospitalier Universitaire de Saint Etienne

Among the 65 studies in Sleep Wake Disorders with a site in France, this one is the 34th largest by planned enrollment of the 42 interventional ones that give a count, is one of 9 that started in 2026, is one of 29 with no phase, reaches primary completion later than 11 of the 26 other live ones, and was the 64th registered.

Sleep Wake Disorders

747 studies on the registry are indexed under Sleep Wake Disorders; 181 are open to participants now.

Browse Sleep Wake Disorders studies →

Open to participants now

22 of the 65 studies in Sleep Wake Disorders with a site in France are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 114 Sleep Wake Disorders studies recruiting now, 40 (35%) set no upper age limit and 53 (46%) stop at 75 or younger; 22 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Sleep Wake Disorders with a site in France, or all of them as a file.
02

Study summary

To diagnose sleep disorders, practitioners primarily use polysomnography (PSG), a precise but costly, cumbersome method that is limited to a single observation. This does not allow for longitudinal monitoring of sleep habits in real-world conditions. An alternative is offered with the C. Santé software receiving information from sensors installed on medical bed. This software analyzes cardiorespiratory parameters and sleep phases without disturbing the patient, enabling continuous and comfortable monitoring. A preliminary study aims to validate the reliability of the C. Santé software analysis, by comparing it to the PSG analysis, considered the gold standard.

03

Conditions studied

  • Sleep Disorder (Disorder)

Browse trials for

Keywords

  • polysomnography
  • BCG
  • Sleep Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged over 18 years.
  • Patients affiliated with or beneficiaries of a social security system.
  • Patients capable of completing all aspects of the study.
  • Patients who have signed for participation in the study

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • Patients suffering from an acute bacterial, fungal, or viral infection.
  • Patients unable to tolerate the placement of the PSG.
  • Patients with psychiatric disorders incompatible with the constraints associated with the need to spend two nights at the clinic.
  • restless legs syndrome
  • Presence of a cardiac pacemaker.
  • Cardiac arrhythmia problems (e.g., complete arrhythmia).
  • Known and treated sleep disorders (e.g., sleep apnea syndrome) or uncontrolled chronic insomnia.
  • Diagnosed dementia.
  • Simultaneous participation in other research studies.
  • Use of medications that could alter sleepiness, including:
  • Sedative-hypnotics.
  • Neuroleptics.
  • Antidepressants.
  • Anxiolytics.
  • H1 antihistamines.
  • Antiepileptics.
  • Opiates and opioid analgesics.
  • Patients under legal guardianship or curatorship.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Polysomnography

    The patients will spend two consecutive nights on the bed equipped with C. Santé software which is also equipped with traditional polysomnography.

    Diagnostic Test: C. Santé software compared to polysomnography

Interventions

  • Diagnostic testC. Santé software compared to polysomnography

    Patients visit the Sleep Unit at the Clinique Mutualiste for sleep disorders. During their consultation with the doctor, a polysomnography scheduled over two consecutive nights is proposed (this applies to any diagnosis of sleep disorders). At that time, they are also invited to participate in the study. After receiving information about the study and signing the consent form, the patient returns for their two consecutive nights equipped with PSG, which they spend on the bed equipped with sensors transmitting information to C. Santé software.

06

What researchers measure

Primary outcomes

  1. The agreement in sleep efficiency measurement performed C. Santé software compared to polysomnography (PSG).

    The study's objective will be met if the sleep efficiency measured by PSG and that calculated from C. Santé software differ by no more than 10%. This means the device will be considered effective if there is at least 90% agreement between PSG and the C. Santé software.

    Time frame: "Up to 3 months after inclusion

Secondary outcomes

  1. Accuracy of RR interval measurement

    Determined from the ECG trace of the PSG compared to the C. Santé software

    Time frame: Up to 3 months after inclusion

  2. Accuracy of sleep phase duration measurement

    Comparing PSG-calculated durations for sleep stages (N1: light slowwave sleep, N2: intermediate slow-wave sleep, N3: deep slow-wave sleep, REM: rapid eye movement sleep) to the C. Santé software calculation for slow-wave sleep (N) and REM.

    Time frame: Up to 3 months after inclusion

  3. Accuracy of respiratory rate measurement

    Comparing C. Santé software measurements to nasal cannula measurements from PSG (analyzed in 30-second intervals)

    Time frame: Up to 3 months after inclusion

  4. Accuracy in positional data

    Comparing the time spent lying on the back or side and the number of position changes as calculated by PSG (via a thoracic accelerometer) and by C. Santé software.

    Time frame: Up to 3 months after inclusion

  5. Differences in measurements across two consecutive nights

    Differences in measurements across two consecutive nights

    Time frame: Up to 3 months after inclusion

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

Of 214 non-industry interventional studies with no phase under Sleep Wake Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 40. This study's planned 2 months is below that.

Counting every sponsor, half of 249 studies reached it within 19 months; a quarter within 6 and three quarters within 37.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 5, 2026
StartEst.
Oct 2026was Jun 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Oct 2026
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Start date Jun 2026→Oct 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07628959
Collaborators
Saint Etienne School of Mine
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Bruno STIMMESSE, MD
Contact
bstimmesse@mutualite-loire.com
(0)4 82 77 48 58 ext. +33
Clara PFENNINGER, CDP
Contact
clara.pfenninger@chu-st-etienne.fr
(0)4 77 12 08 26 ext. +33
Frédéric ROCHE, MD PhD
study chair · CHU de Saint-Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion